Massey Ventures has achieved remarkable recognition at the 2024 Knowledge Commercialisation Australasia (KCA) Research Commercialisation Awards, securing both the Best Licensing Deal award for an innovative keloid scar treatment and the Best Spinout award for NovoLabs®.
The Best Licensing Deal was awarded for Massey Ventures' collaboration with the Gillies McIndoe Research Institute, which developed a new topical treatment for keloid scarring.
In addition to the licensing award, Massey Ventures also celebrated NovoLabs® receiving the Best Spinout award. NovoLabs' Supercritical UV® disinfection technology, developed at Te Kunenga ki Pūrehuroa Massey University, represents a significant advancement in ultraviolet (UV) disinfection applications.
Massey Ventures Commercialisation Manager Dr Dan Carlisle says they’re proud to see Massey Ventures recognised for their hard work and dedication to bringing this technology to market.
“We are proud to see our research commercialisation efforts recognised amongst some incredible finalists from across Australasia. Up against impressive finalists from Australian institutions, we were proud to fly the flag for the New Zealand commercialisation ecosystem.”
Read more here: https://lnkd.in/gQEwiHTD